Lilly Expands Ebglyss into Pediatric Eczema with Strong Phase 3 Results

A major milestone. A younger population. And a growing push into immunology leadership.

Eli Lilly and Company has reported positive Phase 3 results for Ebglyss in children with moderate-to-severe Atopic Dermatitis, setting the stage for a potential label expansion.

What Just Happened?

The Phase 3 ADorable-1 trial hit all key marks.

Key Outcomes at Week 16

• Met primary endpoints:
  • EASI-75 (75% improvement in disease severity)
  • IGA 0/1 (clear or almost clear skin)
• Delivered on secondary endpoints:
  • EASI-90 (near-complete skin clearance)
  • Significant itch reduction

In simple terms: clearer skin, less itching, better quality of life.

Why This Matters?

Atopic dermatitis is especially common—and disruptive—in children.

The Scale

• 9.6 million children affected in the U.S.
• ~1/3 have moderate-to-severe disease

The Gap

• Fewer approved treatments for young children
• Chronic symptoms that impact:
  • Sleep
  • School
  • Daily life

This trial directly targets that unmet need.

The Science: Targeting IL-13

Ebglyss works by blocking a key driver of inflammation.

Mechanism

• Selectively inhibits IL-13, a central cytokine in eczema
• Interrupts the type-2 inflammatory cycle

What That Means?

• Reduced skin inflammation
• Improved skin barrier function
• Less itching and flare-ups

It’s a precision approach to a complex immune condition.

Inside the ADorable-1 Trial

A well-structured pediatric study.

Trial Design

• 363 patients, including infants as young as 6 months
• Randomized to:
  • Ebglyss (weight-based dosing)
  • Placebo
• Background therapy:
  • Topical corticosteroids required initially
  • Reduced/stopped after improvement

Safety Profile

• Consistent with adults and adolescents
• No new safety signals

Most common side effects:

• Upper respiratory infections
• Nasopharyngitis
• Mild injection site reactions

What’s Next?

Lilly is moving fast.

• Regulatory submissions planned in the U.S. and globally
• Additional data coming from:
  • ADorable-1 detailed results
  • ADorable-2 (52-week extension study)

Goal: expand Ebglyss use into younger pediatric populations.

The Bigger Strategy: Lilly’s Immunology Push

This isn’t a one-off success.

Lilly is building a broad dermatology and immunology pipeline, including:

• Next-gen biologics
• Oral small molecules (e.g., IL-17 inhibitors)
• Combination approaches (e.g., with incretins)

Ebglyss is a core asset in that strategy.

Market Position: Competing in a Crowded Space

Ebglyss is already approved for:

• Adults
• Adolescents (≥12 years, ≥40 kg)

Key differentiators:

• Once-monthly maintenance dosing
• Strong efficacy across endpoints
• Potential expansion into younger children

That last point could be a major advantage.

Final Take

This is a textbook lifecycle expansion—backed by strong data.

• Proven drug → new patient population
• High unmet need → clear clinical benefit
• Early results → regulatory momentum

If approved, Ebglyss could:

• Become a go-to biologic for pediatric eczema
• Strengthen Lilly’s position in immunology
• Set a new standard for early intervention in atopic dermatitis

Bottom line: Lilly is not just extending Ebglyss—it’s expanding its impact where it matters most: children.